Verisim Life, Inc.
Oakland, CA Verisim Life, Inc.
- UEI
- YLBHHR2HKLS1
- CAGE
- 8AL17
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4127 Norton Ave, Oakland, CA 94602, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and… | National Institute on Drug Abuse | $1,995,830 | |
| Development of the AI-driven model for anti-SUD drug development based on neuronal plasticity - project summary rates of… | National Institute on Drug Abuse | $1,249,240 | |
| Sbir phase i: rapid repurposing and translation of covid-19 therapeutics using a AI-based biosimulation platform:… | Division of Industrial Innovation | $255,908 |
About Verisim Life, Inc.
Verisim Life, Inc. is a cutting-edge biotechnology company specializing in artificial intelligence and machine learning-driven drug discovery and development platforms. Headquartered in Oakland, California, the company is registered as a minority-owned, woman-owned small business that focuses on developing advanced computational modeling technologies for pharmaceutical research. The company's primary offering is its proprietary BioSim platform, which utilizes AI and machine learning to predict pharmacokinetics, pharmacodynamics, and toxicity profiles of potential drug compounds, with the goal of accelerating drug development and reducing preclinical testing requirements.
Verisim Life, Inc. has secured multiple federal grant awards primarily from the National Institute on Drug Abuse (NIDA) and the National Science Foundation's Division of Industrial Innovation, focusing on critical healthcare challenges. The company's grant-funded projects have concentrated on developing therapeutic solutions for stimulant use disorder (STUD), with a $1,483,186 Phase II grant awarded in July 2025 to expand its AI-driven drug discovery platform for predicting drug parameters targeting the ghrelin-1 pathway. Previously, the company received a Phase I grant in April 2022 to develop AI-driven models for anti-SUD drug development based on neuronal plasticity. Additionally, in January 2021, Verisim Life, Inc. was awarded a $255,908 grant from the National Science Foundation to rapidly repurpose and translate COVID-19 therapeutics using its AI-based biosimulation platform, specifically researching multi-target therapies involving angiotensin-converting enzyme 2 and calcium pathways. These grants demonstrate the company's expertise in applying advanced computational modeling to accelerate drug discovery and development across various critical medical domains.
Quick answers
What is Verisim Life, Inc.'s UEI?
Verisim Life, Inc.'s Unique Entity ID (UEI) in SAM.gov is YLBHHR2HKLS1.
What is Verisim Life, Inc.'s CAGE code?
Verisim Life, Inc.'s CAGE code is 8AL17.
What is Verisim Life, Inc.'s primary NAICS code?
Verisim Life, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Verisim Life, Inc. located?
Verisim Life, Inc.'s physical address in SAM.gov is 4127 Norton Ave, Oakland, CA 94602, USA.
Is Verisim Life, Inc. registered in SAM.gov?
Yes. Verisim Life, Inc.'s SAM.gov registration is active through July 8, 2027.
What is Verisim Life, Inc.'s most recent federal award?
Verisim Life, Inc.'s most recent federal grant award is Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and… (R42DA056084), from National Institute on Drug Abuse, on July 15, 2025.
On GovTribe
See Verisim Life, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors